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Anti-Fas antibodies induce cytolysis and apoptosis in cultured human
mesangial cells. Death of renal cells often occurs during the acute and
resolution phases of some forms of glomerulonephritis. The apoptotic Fas
protein belongs to a recently described family of cytokine receptors with
similarities to tumor necrosis factor (TNF) receptors, and may contribute
to the necrobiology of renal cells. Fas transduces a signal for apoptosis in
sensitive cells after binding by specific antibodies or following contact with
natural Fas ligand. We have studied Fas in cultured human mesangial
cells. Cytoflurography demonstrated Fas expression on the surface of
human mesangiaf cells that was increased by stimulation with interferon
gamma (IFNy). Agonistic anti-human Fas antibodies were cytotoxic to
these cells. Cytotoxicity was time- and dose-dependent, and was modu-
lated by pre-stimulation of the mesangial cells with IFNY and/or by
co-treatment with actinomycin-D. Mesangial cell death following exposure
to anti-Fas antibodies has features consistent with apoptosis, such as
internucleosomal DNA fragmentation, nuclear shrinkage and condensa-
tion, and decreased DNA content. These data suggest that Fas and its
ligand could play a mechanistic role in human glomerular cell injury.
Cell death and apoptosis have been reported to occur both
during kidney development and following kidney injury, particu-
larly following acute renal failure, endotoxemia, and chronic
glomerulonephritis [1—5]. The factors that regulate renal cell
survival in these circumstances are not entirely clear [6]. The Fas
pathway is one such system that warrants further scrutiny. Fas
antigen was originally defined as the target of cytocidal monoclo-
nal antibodies, Fas and APO-1 [7, 81. It was later demonstrated
that Fas belonged to a family of cell membrane receptors that
includes both tumor necrosis factor (TNF) receptors, the low
affinity nerve growth factor (NGF) receptor, CD4O, CD27, CD3O
and others [9]. Some of these proteins regulate the occurrence of
cell death by apoptosis.
Anti-human Fas antibodies induce apoptosis in susceptible
human cells and in murine cells expressing human Fas [1)11, 11].
Anti-murine Fas antibodies also can induce apoptosis in vivo [121.
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However, not all cells expressing Fas are sensitive to Fas-medi-
ated death. For example, some populations of peripheral blood
lymphocytes as well as thymocytes from interleukin-1 converting
enzyme (ICE)-deficient mice are resistant [13, 14]. Moreover, Fas
activation by monoclonal antibodies may induce proliferation of
lymphocytes [15, 161. The ligand for Fas (FasL) has also been
shown to belong to the TNF superfamily of cytokines and to
promote cell death [17—19]. T lymphocytes express FasL and the
ligand may mediate some forms of T cell cytotoxicity [20, 21]. As
T cells are often present at the site of renal damage, we
hypothesized that Fas expressed by mesangial cells (MC) may act
as bridge to cellular damage following human glomerulonephritis,
and accordingly, we studied the cytotoxic effect of anti-human Fas
agonistic antibodies on cultured human MC.
Methods
Cells, cytokines and antibodies
Human MC were isolated from cadaver kidneys deemed un-
suitable for transplantation as previously described [22]. Glomer-
uli were isolated by differential sieving, resuspended in Dulbecco
buffer pH 7.4 and incubated with 300 U/ml of collagenase type IA
(Sigma, St Louis, MO, USA) for 30 minutes at 37°C. Afterwards,
they were placed on culture plates (Costar, Cambridge, MA,
USA) and incubated at 37°C in an atmosphere of 5% CO2 in
RPM! 1640 medium buffered with 25 mM HEPES (GIBCO BRL,
Paisley, Scotland, UK) at pH 7.4 supplemented with 20% de-
complemented fetal calf serum (FCS), 100 U/ml penicillin, 100
g/ml streptomycin, 2 mrvt glutamine and 0.06 U/mI insulin. MC
reached confluency at 21 days, and were used in the fourth or fifth
passage [22]. MC were morphologically characterized by phase
contrast microscopy. This technique showed no evidence of the
presence of either glomeru!ar endothelial or epithelial cells, which
grow in monolayers of polygonal cells. Additionally, the cells
stained with anti-smooth muscle myosin antibodies, but staining
was negative for factor VII!, cytokeratin, and common leukocyte
antigen (Sigma), excluding endothelial, epithelial cell and leuko-
cyte contamination, respectively.
Human recombinant interferon gamma (IFNy) was obtained
from Boehringer Mannhein GmbH, Germany; anti-human Fas
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Fig. 1. Fas receptor expression on the surface of
human MC demonstrated by cytofluorography.
(A) Non-stimulated MC stained with control
1gM (1gM) or anti-Fas antibody (Fas). (B) MC
were stimulated with either control media (Bas)
or IFN7 1000 U (IFN) for 48 hours. IFNy
increased mean fluorescence intensity by 48%.
The relative cell number is plotted against log
fluorescence intensity.
1gM monoclonal antibodies (clone CH-11) and control monoclo-
nal murine 1gM were obtained from Upstate Biotechnology
Incorporated (Lake Placid, NY, USA). Upon binding to the Fas
receptor the CH-11 antibody acted as an agonist and activated the
receptor [8, 16].
Cytofluorography
For cytofluorography, MC were cultured in the presence of
control media or IFNy 1000 U/mi for 24 to 48 hours. This time
point was chosen based on the time-course of Fas expression in
stimulated thymocytes and murine MC [23, 24]. Single cell
suspensions were resuspended in phosphate buffered saline/0.1%
bovine serum albumin. Five X iO cells were incubated for 30
minutes at 4°C with 5 rWml anti-Fas antibody or control 1gM,
followed by incubation for 30 minutes at 4°C with a FITC-
conjugated goat anti-mouse 1gM (Calbiochem, La Jolla, CA,
USA) and analyzed on a cytofluorograph [25]. Dead cells and
debris were excluded from analysis by selective gating based on
anterior and right-angle scatter. At least 10,000 events were
collected for each sample, and data were displayed on a logarith-
mic scale of increasing green-fluorescence intensity. Mean fluo-
rescence intensity was calculated for each sample using LYSIS II
software.
Cytotoxicily assays
The cytotoxicity of anti-human Fas antibodies in MC was
quantified by a 51chromium (51Cr; Amersham, Arlington Heights,
IL, USA) release assay. Although the 51Cr release assay does not
give information on the form of cell death, it has been previously
used to quantitate Fas-induced apoptosis [17, 18]. MC were
cultured in 24-well plates (Costar, Cambridge, MA, USA) and
pre-stimulated for 48 hours with either control media or IFNy
1000 U/ml [26]. After loading with 51Cr, cells were challenged
with control media, control 1gM 500 ng/ml or anti-Fas antibodies
500 ng/ml for 24 hours, in the presence or absence of actinomycin
D 0.2 jxg/ml. Specific 51Cr release was calculated from the
formula:
Specific 51Cr release
Sample 51Cr release — Spontaneous 5tCr release
=
Total 51Cr — Spontaneous 51Cr release
Morphological evidence of apoptosis
For morphological studies MC were cultured in 8-well Labtek
slides (NUNC, Naperville, IL, USA) and treated with anti-Fas 0.5
jxg/ml or control 1gM for 24 hours. Cells were pretreated with
control media or IFN 1000 U/mi for 48 hours. Then, the antibod-
ies were added. In some wells, actinomycin D 0.2 xg/ml was added
30 minutes before the antibodies. Then the cells were washed with
phosphate buffered saline (PBS), fixed in 10% buffered formalin
for 10 minutes, stained with propidium iodide 1 .rg/ml in PBS, in
the presence of RNAse A 100 jxg/ml for 30 minutes at 37°C,
mounted in 90% glycerol/PBS and observed by fluorescence
microscopy [27]. Quantification of the percentage of apoptotic
nuclei (small, bright and fragmented) was performed in at least
1000 cells of triplicate samples by an observer who was blinded as
to the nature of the stimuli.
DNA fragmentation
Genomic DNA was obtained by lysing cells in hypotonic lysis
buffer (100mM NaCI, 10mM Tris, 1 mrvi EDTA, 1% SDS, in PBS,
pH 7.2) with proteinase K 200 xg/ml overnight at 37°C. DNA was
precipitated, resuspended, separated in a 1.5% agarose gel and
stained with ethidium bromide [28].
Flow cytometly assessment of cell death
Cellular DNA content was assessed by flow cytometry. For that
purpose, cells were cultured in 12-well plates and stimulated as
appropriate. Cells attached to the plate were collected with 2.2
mM EDTA in PBS pH 7.2, and mixed with detached cells present
in the supernatant. Cells were spun and resuspended in solution
containing 100 tg/ml propidium iodide, 10 g/ml RNAse A,
0.05% NP-40 in PBS; then they were incubated at 4°C for one
hour, and analyzed on the FACScan using LYSIS II software. The
percentage of cells with decreased DNA staining (A0), comprising
apoptotic cells due to either fragmentation or decreased chroma-
tin [29], was counted. Cells with very low DNA content, in which
the mode of cell death could not be ascertained, were excluded
from analysis.
Statistics
ANOVA was used to compare means. Results are expressed as
mean SEM with a significance of P < 0.05.
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Fig. 2. Agonistic anti-human Fas antibodies are
cytotoxic to cultured human MC. (A) Human
MC pretreated with IFNy 1000 U/mI for 48
hours and then challenged with control 1gM
remain confluent and attached to the plate
(right). By contrast, MC pretreated with IFNy
and then challenged with anti-human Fas
antibody 0.5 g/ml for 24 hours are no longer
confluent, and numerous detached cells can be
observed (left). Loss of adhesion to other cells
and to culture substrata is an early feature of
apoptosis [30]. Phase contrast microscopy (X
400). (B) A dose response curve demonstrates
the minimal dose of anti-Fas antibodies to elicit
significant cytotoxicity at eight hours in non-
stimulated MC was 0.5 jg/ml. *P < 0.05. 5tCr
release has previously been used to assess cell
death induced by Fas ligand [17, 18]. (C) The
cytotoxic response at 24 hours to 0.5 j.Lg/ml
anti-Fas antibodies was increased by co-
treatment with actinomycin D 0.2 .tWml or by
pre-stimulation with IFNy 1000 U/mI for 48
hours. Cells were stimulated with either IFNy
or control media for 48 hours. Thereafter, anti-
Fas, 1gM and actinomycin D were added and
51Cr release measured at 24 hours. A control
murine monoclonal 1gM 0.5 j.tml was not
toxic even in IFN7 stimulated cells. Results are
expressed as specific 51Cr release. Mean SCM
of quadruplicate wells from a representative
experiment. *p < 0.05 versus 1gM control, **p
< 0.05 versus anti-Fas and versus their
respective controls.
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Fig. 3. MC death induced by anti -Fas antibodies has features of apoptosis. (A) Normal MC stained with propidium iodide display pale nuclei (right).
The same technique demonstrates typical shrunk and bright nuclei (arrows) in anti-Fas exposed cells (left), suggestive of cell death by apoptosis. (B)
Genomic DNA obtained from MC treated with anti-Fas 0.5 g/ml for 24 hours displayed internucleosomal DNA fragmentation, while DNA from
control MC was in a high molecular weight form. (C) Flow cytomctry analysis of DNA content in propidium iodide stained cells demonstrated the
presence of a hypodiploid peak (A0) among cells treatcd with actinomycin and/or anti-Fas for 24 hours, but not in non-treated controls. The A{) peak
includes apoptotic cells that have lost DNA because of fragmentation. The combination of actinomycin D 0.2 j.g/ml and anti-Fas 1 g/ml greatly
increased the percentage of apoptotic cells.
Results
Fas is expressed by human MC
Cytofluorography demonstrated FAS expression in primary
cultures of human MC (Fig. 1A). Staining with anti-Fas antibody
produced sixfold more intensity than did control antibody in
nonstimulated cells. Mean fluorescence increased by 7% and 48%
after stimulation with IFNy 1000 U/mi for 24 and 48 hours,
respectively (Fig, IB).
Agonistic anti-human Fas antibodies are cytolytic for human MC
Agonistic anti-human Fas antibodies were toxic to MC. As
shown in Figure 2A, cells treated with anti-Fas antibodies became
detached as observed by contrast phase microscopy [8]. Loss of
contact from neigboring cell and culture substrata is an early
feature of apoptosis [30]. The minimal dose to elicit significant
cytotoxicity in MC, as assessed by a 51Cr release assay, was 500
nglml (13.2 1.8% specific 51Cr release at 8 hr, P < 0.05 vs.
control; Fig. 2B). Both the time-course and dose-response of
anti-Fas induced toxicity in MC are in accordance to previously
reported data in extrarenal cells [10, 31]. Pretreatment with IFNy
1000 U/mI for 48 hours increased the cytotoxic effect of anti-Fas
antibodies (39 4.6% at 24 hr, P < 0.05 vs. anti-Fas alone), while
IFNy alone had no effect on cytotoxicity (0.7 2%; Fig. 2C). The
cytotoxic effect was more evident in cells to which actinomycin D
0.2 g/m1 had been added 30 minutes before the antibodies (79.5
3.2%, P < 0.001 vs. antibody alone), while actinomycin per se
was modestly toxic (10.8 3.9%; Fig. 2C). A similar concentra-
tion of control mouse monoclonal 1gM was not toxic (3.2 1.2%
at 24 hr), even after prestimulation of the cells with IFNy for 48
hours (—8.5 2.2).
Agonistic anti-human Fas antibodies induce apoptosis of
human MC
Observation of the typical apoptotic morphology (bright, small,
fragmented nuclei) by propidium iodide staining (Fig. 3A) and the
demonstration of internucleosomal DNA fragmentation (Fig. 3B)
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Fig. 4. Agonistic anti-human Fas antibodies induce apoptosis in cultured
human MC. (A) The capacity of anti-Fas to induce the apoptotic mor-
phology in MC and the potentiating effect of actinomycin D and IFNy was
confirmed when cells that remained attached to the culture slide were
fixed and stained with propidium iodide and the percentage of apoptotic
nuclei was calculated. Mean SEM of three experiments. p < 0.001
versus 1gM control, * *p < 0.001 versus anti-Fas and versus their respec-
tive controls. (B and C) Dose-response and time-course of anti-Fas
induced apoptosis in human MC in the presence of actinomycin D 0.2
g/ml. B. MC were stimulated with different concentrations of anti-Fas
antibody for 24 hours. The percentage of cells with apoptotic nuclei was
24 24 Hours calculated. C. Time course of anti-Fas induced cell death. Apoptosis was
noted in MC exposed to 1 pg/mI anti-Fas antibody and actinomycin D 0.2Control pg/mI at two hours and increased further at 8, and 24 hours.
following exposure to anti-human Fas antibody suggested that cell
death was due to apoptosis. The percentage of apoptotic nuclei
was also calculated in MC grown on glass slides and stained with
propidium iodide. Anti-Fas antibodies (0.5 pg/mi) induced the
apoptotic morphology in human MC (at 24 hr: 3.53 0.3 vs. 0.06
0.06% apoptotic nuclei in controls treated with 1gM, P <
0.001). Pretreatment with IFNy 1000 U/mi for 48 hours (Fig. 4A)
increased the percentage of apoptotic nuclei induced by anti-Fas
antibodies (5.5 0.5%, P < 0.001 vs. anti-Fas alone), while IFNy
plus 1gM had no effect (0.07 0.07%). Cells to which actinomycin
D 0.2 .tg/ml had been added 30 minutes before the antibody were
more sensitive to anti-Fas induced apoptosis (11.9 1.5%, P <
0.001 vs. antibody alone), while actinomycin D also induced a mild
degree of apoptosis (0.9 0.3%). Dose- and time-response curves
were analyzed in the presence of actinomycin D (Fig. 4 B, C).
Anti-Fas antibodies 0.5 pg/mI also induced apoptosis in cells
cultured in serum-free conditions (at 24 hr control 0.3 0.12,
anti-Fas 2.3 0.23%, P < 0.01; data not shown).
Flow cytometry of propidium iodide stained cells demonstrated
that treatment with anti-Fas antibodies increased the proportion
of cells with a low DNA content (A0). A() comprises apoptotic
cells which have lost DNA due to either fragmentation or
decreased chromatin [29]. For these studies both attached and
detached cells were used. As apoptoptic cells tend to detach from
culture substrata [30], the percentage of apoptotic cells measured
by this method is higher than that calculated in propidium iodide
stained attached cells. However, the expected increment in mor-
talilty was maintained. Thus, anti-Fas alone or actinomycin D
alone increase the percentage of A cells threefold at 24 hours,
while the combination increased the percentage of A0 cells over
30-fold (37% of the cells at 24 hr; Fig. 3C).
Discussion
Cell death from apoptosis is now recognized during the course
of various renal diseases as well as in early kidney development
[1—5]. Evidence of apoptosis in the glomerulus was reported as
early as 1988 [2, 4], and more recently the presence of apoptotic
cells was noted in experimental anti-Thy-i glomerulonephritis [5].
The Fas-FasL system induces cell death in susceptible extrarenal
cells and may regulate cell survival in the kidney. Activation of
target cell Fas has a role in T cell cytotoxicity [20, 21]. Normal rat
kidneys are a source of FasL [17, 24]. We have subsequently
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described Fas expression inmurine MC [24]. We now report that
cultured human MC express Fas and that activation of this
receptor triggers cell death.
Agonistic anti-Fas antibodies were toxic to nonstimulated hu-
man MC. The time course of this toxic effect is similar to that
previoulsy observed in those extrarenal cells that are undergo
apoptosis upon stimulation of the Fas receptor. In those nonrenal
cells signs of cytotoxicity and cell detachment may be observed by
phase-contrast microscopy or dye uptake assays two hours after
addition of anti-Fas [8, 31, 321. However, cultured human MC
appear to be less sensitive to Fas induced death than some of the
previously reported cell lines [10]. Low dose actinomycin D
further sensitized them to anti-Fas induced apoptosis. This effect
of actinomycin D had previously been noted in other cells exposed
to either anti-Fas or TNF [8], and suggests that there are
intracellular macromolecules that protect MC from Fas-induced
death. There is evidence that factors other than surface expression
of Fas, modulate the cell sensitivity to Fas-induced death [13—16,
33—36]. Some tumor cell lines expressing Fas [33, 34], in vitro-
stimulated T and B cells, freshly isolated CD45RO T cells, and
ICE-deficient thymocytes [13, 14] are resistant to anti-Fas induced
apoptosis. It has been suggested that high levels of Bcl-2, espe-
cially in the presence of high Bag-i expression, protect from Fas
induced death [15, 32, 35]. Other members of the Bcl-2 family of
proteins expressed by MC, such as Bcl-x [37] may also have a role.
Additionally a newly discovered protein tyrosine phosphatase,
FAP-i, protects from Fas-induced death [36]. Pre-stimulation
with a factor that increased Fas expression, IFNy, also increased
MC mortality upon challenge with anti-Fas antibodies. The
reasons for this may be that a critical amount of Fas receptors may
be required to signal toxicity in MC [31].
Apoptosis appears to be responsible for at least some of the cell
death induced by anti-Fas antibodies in human MC, as the typical
apoptotic morphology and DNA fragmentation could be demon-
strated. Moreover, quantification of the apoptotic bodies showed
that anti-Fas increased the percentage of apoptotic cells. Both
actimomycin-D and IFNy increased anti-Fas induced apoptotic
cell death. However, the percentage of apoptotic cells was lower
than the specific 51Cr release. This difference may be accounted
for by the fact that the apoptotic morphology may only be
detected for a limited period of time [38]. Moreover, as apoptotic
cells detach from culture substrata, some apoptotic cells may have
been washed away during the staining procedure. Indeed, when
attached and detached cells were pooled and the DNA content
analyzed by flow cytometry, the presence of apoptotic cells in the
group treated with anti-Fas was confirmed, and the percentage of
apoptotic cells was higher than among attached cells.
The 51Cr release cytotoxicity test does not give information on
the mode of cell death induced by anti-Fas in MC. Although
apoptotic cells are thought to maintain their cell membrane
integrity longer than necrotic cells, they eventually lose it [30].
Studies of Fas-induced apoptosis and of the protective effect of
apoptosis-related genes against cell death induced by activation of
Fas or other stimuli routinely assess cell death by 51Cr release or
trypan blue exclusion [17, 18, 32, 35]. The capacity of Fas ligand to
induce apoptosis has also been quantified by 51Cr release [17, 18].
Another method based on cell membrane integrity, trypan blue
exclusion, has also been used to demonstrate the protective effect
of the anti-apoptotic genes bcl2 and bag-i against anti-Fas
induced cell death [32, 35]. This has led to the coining of the term
"apoptotic cell lysis" [39].
Our data suggest that Fas activation may be a cause of MC
death in the course of glomerular damage, especially when MC
have been activated by cytokines such as IFN7. In this sense, T
lymphocytes that infiltrate the kidney [40] may be sources of FasL
during glomerular damage. Additionally, macrophages and renal
cells also express the FasL gene [24]. We might envision a posible
role for Fas-induced MC death at several stages of glomerular
damage. Death induced by Fas activation might be a first step in
the course of renal injury. Indeed, acute MC depletion induced by
other pathogenetic mechanisms (complement-mediated lysis) is
the basis for experimental mesangiolysis [5]. Although mesangi-
olysis has been identified in humans in association with glomeru-
lar lymphocyte infiltration [41], its pathogenesis is unclear, Loss of
MC induced by Fas activation could also participate in the
resolution of glomerular hypercellularity. Apoptosis is thought to
play a major role in this process [5]. The persistence of an
increased rate of cell death after normal glomerular cellularity has
been restored may lead to progression of glomerular injury to a
stage of chronic cell depletion, namely, glomerular sclerosis.
Fas may also have other actions in renal cells, besides cell
death. In lymphocytes the activation of Fas can promote cell
proliferation, when the cytokine microenvironment is permissive
or when Bcl-2 expression is high [15, 16]. Activation of related
receptors, such as the 55p TNF receptor [9], triggers a wide variety
of cellular responses in MC. It is conceivable that activation of Fas
by sublethal concentrations of its ligand may also trigger non-toxic
cell responses. Thus, additional roles of Fas in renal disease may
be envisioned.
Finally, cell death induced by Fas is regulated by several
intracellular proteins [14, 33, 36, 37] that may be targeted
therapeutically, if a role for Fas in human renal disease is
confirmed. The future availability of recombinant FasL or specific
antagonists, such as recombinant soluble Fas [42] may help to fully
characterize the possible role of the Fas-FasL system in human
renal pathophysiology.
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